CRISPR Therapeutics

Casgevy is finally scaling. Revenue hit 76 million dollars in the second quarter of 2026, up 78 percent from just three months earlier and up 151 percent from a year ago. It is now approved in 39 countries, and regulators just cleared it for children as young as two, which opens the door to roughly 5,500 more patients who could not be treated before.

The money story is getting better fast. The company lost 91 million dollars this quarter, less than half the 209 million dollar loss a year ago, while research spending actually fell slightly to 67 million dollars. Growing sales with flat costs is exactly the pattern you want to see from a young medical company.

CRISPR does not own its own blockbuster outright. Partner Vertex runs the manufacturing and selling of Casgevy and keeps 60 percent of the profits, leaving CRISPR with 40 percent. That partnership cost CRISPR 40 million dollars this quarter, so even as sales climb, a big slice of the upside walks out the door.

One approved drug is carrying a company valued near 5 billion dollars. Everything else, the heart, liver, cancer, autoimmune, and diabetes programs, is still in early human testing, including two brand new trials just started for high blood pressure and a rare lung and liver disease. Early trials fail often, and the stock swings hard on every result.